What's in Genentech, Inc.'s pipeline?

Genentech, Inc. has 136 drugs in our index: 6 marketed, 0 filed, 12 in Phase 3, 32 in Phase 2, 86 in Phase 1.

Which companies overlap with Genentech, Inc.'s portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, GlaxoSmithKline, Pfizer, AstraZeneca, Hospital Clinic of Barcelona.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/genentech-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Genentech, Inc. — Portfolio Competitive Intelligence Brief

Genentech, Inc. pipeline: 6 marketed, 0 filed, 12 Phase 3, 32 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 12 Phase 3 32 Phase 2 86 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cathflo Activase (Alteplase)	Cathflo Activase (Alteplase)	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen	Cardiovascular / Interventional
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf	Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf	marketed	Endoglycosidase [EPC]
Tetanus Toxoid Adsorbed Vaccine	Tetanus Toxoid Adsorbed Vaccine	marketed	Toxoid vaccine	Tetanus toxin (tetanospasmin)	Immunology
Asthma therapies	Asthma therapies	marketed	Monoclonal antibodies (multiple agents with different targets)	IgE, IL-5, IL-4 receptor alpha (varies by specific agent)	Respiratory / Immunology
Raptiva (efalizumab)	Raptiva (efalizumab)	marketed	Monoclonal antibody; integrin inhibitor	CD11a (LFA-1 alpha subunit)	Immunology/Dermatology
oseltamivir [Tamiflu]	oseltamivir [Tamiflu]	marketed
Ocrelizumab Dose 2 and Dose 3	Ocrelizumab Dose 2 and Dose 3	phase 3	CD20-depleting monoclonal antibody	CD20	Immunology
Dexamethasone Mouth Rinse	Dexamethasone Mouth Rinse	phase 3	Corticosteroid	Glucocorticoid receptor	Immunology / Dermatology / Oral Medicine
rhuFab V2 (ranibizumab)	rhuFab V2 (ranibizumab)	phase 3	VEGF inhibitor	VEGF-A	Ophthalmology
Tarceva (erlotinib HCl)	Tarceva (erlotinib HCl)	phase 3	EGFR tyrosine kinase inhibitor	EGFR	Oncology
Methyloprednisolone	Methyloprednisolone	phase 3			Other
[18F]MK-6240	[18F]MK-6240	phase 3

Therapeutic area mix

Immunology · 4
Oncology · 3
Immunology/Dermatology · 1
Ophthalmology · 1
Other · 1
Pain Management, Allergy/Immunology · 1
Respiratory · 1
Respiratory / Immunology · 1
Cardiovascular / Interventional · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 5 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Pfizer · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Hospital Clinic of Barcelona · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Chiesi Farmaceutici S.p.A. · 2 shared drug classes
Fondation Ophtalmologique Adolphe de Rothschild · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Genentech, Inc.:

Cite this brief

Drug Landscape (2026). Genentech, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genentech-inc. Accessed 2026-05-13.